María Esteve Pardo-rekin lankidetzan egindako argitalpenak (26)

2024

  1. Bacille Calmette-Guérin vaccination to prevent febrile and respiratory illness in adults (BRACE): secondary outcomes of a randomised controlled phase 3 trial

    eClinicalMedicine, Vol. 72

  2. Sex-Related Differences in the Phenotype and Course of Inflammatory Bowel Disease: SEXEII Study of ENEIDA

    Clinical Gastroenterology and Hepatology, Vol. 22, Núm. 11, pp. 2280-2290

  3. Specific and off-target immune responses following COVID-19 vaccination with ChAdOx1-S and BNT162b2 vaccines—an exploratory sub-study of the BRACE trial

    eBioMedicine, Vol. 103

2023

  1. Bacillus Calmette-Guérin vaccination for protection against recurrent herpes labialis: a nested randomised controlled trial

    eClinicalMedicine, Vol. 64

2022

  1. Risk of Immunomediated Adverse Events and Loss of Response to Infliximab in Elderly Patients with Inflammatory Bowel Disease: A Cohort Study of the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 16, Núm. 6, pp. 946-953

2021

  1. Clinical features, therapeutic requirements and evolution of patients with Crohn’s disease and upper gastrointestinal involvement (CROHNEX study)

    Alimentary Pharmacology and Therapeutics, Vol. 54, Núm. 8, pp. 1041-1051

2020

  1. Effectiveness and Safety of the Sequential Use of a Second and Third Anti-TNF Agent in Patients with Inflammatory Bowel Disease: Results from the Eneida Registry

    Inflammatory Bowel Diseases, Vol. 26, Núm. 4, pp. 606-616

2019

  1. Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial

    Therapeutic Advances in Gastroenterology, Vol. 12

  2. Differences between childhood- and adulthood-onset inflammatory bowel disease: the CAROUSEL study from GETECCU

    Alimentary Pharmacology and Therapeutics, Vol. 49, Núm. 4, pp. 419-428

2018

  1. Post-operative morbidity and mortality of a cohort of steroid refractory acute severe ulcerative colitis: Nationwide multicenter study of the GETECCU ENEIDA Registry

    American Journal of Gastroenterology, Vol. 113, Núm. 7, pp. 1009-1016

2017

  1. Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study

    American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131

  2. Long-Term Efficacy and Safety of Cyclosporine in a Cohort of Steroid-Refractory Acute Severe Ulcerative Colitis Patients from the ENEIDA Registry (1989-2013): A Nationwide Multicenter Study

    American Journal of Gastroenterology, Vol. 112, Núm. 11, pp. 1709-1718

2015

  1. Thiopurine Therapy Reduces the Incidence of Colorectal Neoplasia in Patients with Ulcerative Colitis. Data from the ENEIDA Registry

    Journal of Crohn's & colitis, Vol. 9, Núm. 12, pp. 1063-1070

2014

  1. Disease severity in familial cases of IBD

    Journal of Crohn's and Colitis, Vol. 8, Núm. 3, pp. 234-239

  2. Phenotypic concordance in familial inflammatory bowel disease (IBD). Results of a nationwide IBD Spanish database

    Journal of Crohn's and Colitis, Vol. 8, Núm. 7, pp. 654-661

  3. Risk of colectomy in patients with ulcerative colitis under thiopurine treatment

    Journal of Crohn's and Colitis, Vol. 8, Núm. 10, pp. 1287-1293

2013

  1. Safety of thiopurine therapy in inflammatory bowel disease: Long-term follow-up study of 3931 patients

    Inflammatory Bowel Diseases, Vol. 19, Núm. 7, pp. 1404-1410

  2. Smoking does influence disease behaviour and impacts the need for therapy in Crohn′s disease in the biologic era

    Alimentary Pharmacology and Therapeutics, Vol. 38, Núm. 7, pp. 752-760

2012

  1. Effectiveness of infliximab after adalimumab failure in Crohn's disease

    World Journal of Gastroenterology, Vol. 18, Núm. 37, pp. 5219-5224

  2. Long-term durability of response to adalimumab in Crohn's disease

    Inflammatory Bowel Diseases, Vol. 18, Núm. 4, pp. 685-690